Skip to content

OIS@ASCRS 2016 On-Demand

OIS@ASCRS 2016 On-Demand

Summit Kick Off With Ophthalmology Innovation Cycle & Financing Update

William J. Link, PhD, Managing Director – Versant Ventures

Ophthalmology Innovation Showcase

Moderators:
Susan Benton, Head, Ophthalmics Business Development – Shire
Jerry St. Peter, VP & Head, Ophthalmic Business – Sun Pharmaceutical Industries

View Company Presentations

PowerVision

PowerVision has developed a fluid-controlled accommodating IOL designed to restore youthful vision. The FluidVision™ AIOL provides True Accommodation™ by mimicking the eye’s natural accommodative process to transport fluids inside it, creating true shape change. The Company has shown in clinical trials that it can deliver clear vision at all distances.

Refocus Group

Refocus Group, Inc. is a medical device company engaged in the research and development of treatments for presbyopia. Our mission is to become the preferred surgical alternative for the treatment of presbyopia in pre-cataract patients. The VisAbility™ Implant System is the surgical correction of presbyopia without compromise to distance vision.

ReVision Optics

ReVision Optics®, Inc. is developing and commercializing an innovative optical solution to correct presbyopic vision, or the inability of the eye to focus on near objects.

Encore Vision

Encore Vision is a privately funded ophthalmic pharmaceutical company developing EV06 Ophthalmic Solution (EV06) to treat presbyopia. Encore Vision has completed a Phase I/II Prospective, Randomized, Double-Masked, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of EV06 in Improving Distance Corrected Near Vision in Subjects with Presbyopia.

ClarVista Medical

ClarVista Medical is a clinical stage ophthalmic device company focused on development of the HARMONI modular intraocular lens system. The modular design of the HARMONI IOL system provides enhanced stability during the healing process and enables long term refractive care with atraumatic optic exchange for the life of the patient.

Mynosys Cellular Devices

Product – ZeptoTM is a disposable automated capsulotomy device that provides surgeons with consistent, well-centrated, and accurate capsulotomies without interrupting surgical routine and patient flow. ZeptoTM uses a highly focused, fast multipulse low energy discharge to instantaneously produce a perfectly round anterior capsulotomy simultaneously everywhere along 360 degrees.

International Biomedical Devices

IBMD is an early-stage medical device company focused in ophthalmology innovations. The company is leading the emerging, non-laser based, precision capsulotomy category through the development of a unique capsulotomy technology. ApertureCTC™ represents a considerable improvement to traditional surgical techniques by ensuring safe and precise capsulotomies and predictable outcomes for patients.

Cassini

Cassini is a novel corneal shape analyser that uses patented color LED ray-tracing technology to measure Total Corneal Astigmatism (TCA) including the posterior cornea. This information drives the selection of premium IOL’s and (femto-laser generated) Arcuate Incisions to achieve spectacle free cataract surgery results and increase premium patient volume.

TearScience

TearScience, a medical device company, has pioneered technologies and innovation that improves evaluation and treatment of MGD. A progressive, obstructive disease and a root-cause of dry eye, MGD is distinguished by loss of function and structure of tear oil glands. MGD affects approximately 86% of the dry eye sufferers worldwide.

Aerie Pharmaceuticals

Aerie is a clinical-stage pharmaceutical company focused on discovery, development and commercialization of first-in-class therapies for patients with glaucoma and other diseases of the eye. Aerie’s two lead products, RhopressaTM and RoclatanTM, are once daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma and ocular hypertension.

ForSight VISION5

ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major eye diseases. The lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually.

Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases of the eye using its proprietary hydrogel platform technology. The Company’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and allergic conjunctivitis, and Phase 2 for glaucoma and inflammatory dry eye disease. The Company is also evaluating sustained-release anti-VEGF depots. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Avedro

Avedro is a privately held pharmaceutical and medical device company advancing the science and technology of corneal cross-linking and refractive correction. Avedro’s Photrexa Viscous, Photrexa and KXL products are approved for sale in the United States for the treatment of progressive keratoconus.

Diagnostics-Impact on the Premium Channel: Market Overview

Richard Lindstrom, MD

Diagnostics-Impact on the Premium Channel: Company Presentations

Moderator:
Richard Lindstrom, MD

View Company Presentations

TearLab

TearLab Corporation develops and markets lab-on-a-chip technologies enabling eye care practitioners improved patient care by objectively and quantitatively testing for tear disease markers at point-of-care.

Alcon

Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.

Carl Zeiss Meditec AG

Carl Zeiss Meditec, a world-leading medical technology company, supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete solutions for diagnosis and treatment of eye diseases, innovative visualization solutions for microsurgery, and promising, future-oriented technologies such as intraoperative radiotherapy.

Heidelberg Engineering

Heidelberg Engineering is an imaging solutions company which designs, manufactures, and distributes diagnostic instruments for eye care professionals. The company’s products are used by ophthalmologists and optometrists to scan patients’ eyes for signs of disease and to assist in the management of patients found to have disease.
The company’s core technologies include confocal microscopy, scanning lasers and optics, optical coherence tomography, software image analysis and IT solutions for image management.
Heidelberg Engineering is a privately held company, headquartered in Heidelberg, Germany. The company distributes its products through a network of subsidiaries and distribution partners in most countries of the world.

Diagnostics-Impact on the Premium Channel: Panel Discussion

Moderator:
Richard Lindstrom, MD

Participants:
Tom Frinzi, President – AMO, SVP – Abbott Laboratories
Dave Harmon, President – Market Scope
Warren Hill, MD
Ludwin Monz, PhD, President & CEO – Carl Zeiss Meditec AG
Jay Pepose, MD, PhD
Vance Thompson, MD

View Session

Spotlight on the Premium Channel: Market Overview & Pannel Discussion

Moderator:
Elizabeth Yeu, MD

Participants:
David Chang, MD
Eric Donnenfeld, MD
Sherman Reeves, MD, MPH
Denise Visco, MD

View Session

Spotlight on the Premium Channel: Company Presentations

Moderator:
Elizabeth Yeu, MD

View Company Presentations

AcuFocus

AcuFocus, an ophthalmic medical device company, develops and markets small aperture technologies. Their two first of a kind products, the KAMRA® inlay and the IC-8 IOL, are designed to provide patients with an extended range of vision. The KAMRA inlay is the first FDA approved corneal inlay.

Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.

Abbott Medical Optics

Abbott offers a comprehensive portfolio of cataract, refractive and eye care products. Cataract products include laser cataract technology, intraocular lenses, phacoemulsification systems and viscoelastics. Refractive products include wavefront diagnostic devices, femtosecond lasers and excimer laser vision correction systems. Eye care products include disinfecting solutions, lens rewetting drops and artificial tears.

Alcon

Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.

OIS Lifetime Innovator Award

Recipient:
Roger Steinert, MD

Interviewed By:
Stephen Lane, MD

View Session

WTF@OIS: What’s the Future @OIS?: Overview

Unconventional innovations challenging conventional wisdom

Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD

WTF@OIS: What’s the Future @OIS?: Company Presentations

Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD

View Company Presentations

Equinox

Equinox is a preclinical medical device company is developing a non-pharmacologic, non-surgical device to treat glaucoma and other diseases of the optic nerve head. Capitalizing on the recent discoveries that glaucoma is likely a 2 pressure disease caused by an imbalance between intraocular pressure and intracranial pressure, Equinox is restoring homeostatic balance to the optic nerve, by balancing the pressurized fluids surrounding the optic nerve.

Presbyopia Therapies

Presbyopia Therapies has developed a therapy for daily treatment of presbyopia. “Liquid Vision” (trademarked) has one issued patent and several pending applications based on discoveries combining aceclidine with tropicamide that may provide a new era of long lasting, powerful topical presbyopic treatment with both improved near and distance vision for total depth of focus enhancement. Liquid Vision represents a potential series of industry firsts: Binocular treatment, Approximately 30 minute onset, 6 hour duration, Improves near vision without blurring distance vision, Pupil constriction without ciliary brow ache and Daily use or as needed. Phase 2B completion planned for fall 2017.

Stroma Medical

STRŌMA Medical Corporation is a clinical stage, ophthalmic medical device company focused on a safe effective way to permanently change eye color. STRŌMA uses a combination of amplified light modalities with an iris mapping and tracking system, in a proprietary system to disrupt the pigment that covers the anterior iris and allow the normal aqueous flow to remove the pigment changing a brown or hazel eye into a blue eye. The market for eye color change will be a multi-billion opportunity worldwide and the company has an experience management prepared to help ophthalmic surgeons take advantage of this opportunity.

Eyenovia

Eyenovia is a specialty biopharmaceutical company developing breakthrough ophthalmic therapies for eye diseases such as glaucoma. Eyenovia’s is using its proprietary piezo-static precision delivery technology to build a portfolio of highly differentiated micro-therapeutics for the eye across multiple indications. Eyenovia is moving several programs forward in late stage clinical development for the treatment of glaucoma.

Wicab

Wicab, Inc., a privately held company located in Middleton, Wisconsin, was founded in 1998 to advance the research and development of sensory substitution devices based on the display of information on the tongue using electro tactile stimulation. Our newest product, the BrainPort® V100 Vision Aid, provides information to blind individuals via a neuro-stimulating array placed on the tongue. This unique device provides immediate benefits to its blind users in areas of safety, mobility, and independence.

Spotlight on MIGS: MIGS is Growing Up – A Market Assessment

Ike Ahmed, MD

Spotlight on MIGS: Company Presentations

Moderator
Ike Ahmed, MD

View Company Presentations

Taking a MIGS Company Public: Glaukos

Glaukos® Corporation is an ophthalmic medical technology company located in Laguna Hills, California, that is dedicated to researching and developing micro-technologies to improve glaucoma therapy and has developed the iStent® Trabecular Micro-Bypass Stent. The FDA-approved iStent is intended to reduce IOP in patients with mild-to-moderate open-angle glaucoma.

Acquiring a MIGS company: Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

FDA and MIGS evolving guidance: Transcend

Transcend Medical is focused on the development of technologies to transform the treatment of glaucoma, the leading cause of adult irreversible blindness. Our flagship product, the CyPass® Micro-Stent, is a next-generation, minimally invasive device designed to enhance aqueous outflow to the suprachoroidal space, part of the eye’s natural drainage systems.

Differentiating MIGS devices and the cataract surgeon: Ivantis

Ivantis is a privately held company established in 2007 to design, develop and commercialize new technologies to treat eye disease. The flagship technology is the Hydrus™ Microstent, a novel MIGS device to treat glaucoma that has been used in over 2,500 procedures in 22 countries with 75 surgeons.

Glaucoma device development beyond MIGS: InnFocus

InnFocus MicroShunt® in Final Phase FDA trials treating largest glaucoma segment; achieved mean post op IOP’s below 15 mm Hg, and 80% med reduction. IOP reduction at 3 months similar to 3 year.

Over 35 doctors treated more than 240 patients in 7 countries, followed for up to 5 years.

Spotlight on MIGS: Panel Discussion

Moderator:
Ike Ahmed, MD

Participants:
Robert Cionni, MD
Richard Lewis, MD
Jai G. Parekh, MD, MBA

View Session

Masters of the Universe: Panel

Moderator:
Jim Mazzo, Executive Chairman & CEO – AcuFocus

Participants:
Mike Ball, CEO – Alcon
Tom Frinzi, President – AMO, SVP – Abbott Laboratories
William J. Link, PhD, Managing Director – Versant Ventures
Ashley McEvoy, Company Group Chairman – Johnson & Johnson Vision Care
William Meury, EVP, President Branded Pharma – Allergan
Ludwin Monz, PhD, President & CEO – Carl Zeiss Meditec AG
Calvin Roberts, MD, SVP & Chief Medical Officer – Bausch + Lomb

Scroll To Top